Effects of berberine administration on insulin resistance, lipid profile and general health - Narrative Review
DOI:
https://doi.org/10.12775/JEHS.2025.82.60324Keywords
berberine, insulin sensitivity, lipid profile, overall health, type 2 diabetes, dyslipidemia, metabolic syndrome, cardiovascularAbstract
Introduction and purpose: Berberine is a bioactive substance of natural origin that can be found in various plants. It has been used in natural medicine for ages. Recent studies have shown its potency in improving insulin resistance, lipid profile, carbohydrate metabolism and overall health. It also shows promise for aiding in weight management. This review aims to summarise current evidence and research on effects mentioned above based on various studies and their findings.
Materials and Methodology: A comprehensive literature search was conducted using different databases such as PubMed, Medline, Cochrane Library, Clinical Key, Springer, MDPI, Google Scholar. Studies that evaluated effects mentioned above were included. Extraction of the data was focused on key findings, dosage of berberine, duration of supplementation, study, dosing and characteristics of examined populations.
Results: Evidence found suggests that berberine significantly improves insulin sensitivity. It does so by modulation of molecular pathways. Including activation of AMP-activated protein kinase( AMPK) and improvement in expression of insulin receptor. In addition berberine exhibits beneficial influence on blood pressure, lipid profile and inflammatory markers. However the differences in population characteristics and study designs can have significant importance and can’t be overlooked.
Conclusions: Berberine appears to be an effective alternative for conventional treatments in managing blood glucose levels, improving lipid profile and overall health by showing lots of beneficial properties. Yet to come to such conclusions further large-scale, long- term, randomised, controlled clinical trials are needed.
References
1. Gao Y, Wang F, Song Y, et al. The status of and trends in the pharmacology of berberine: a bibliometric review [1985–2018]. Chin Med. 2020;15(1):7. doi:10.1186/s13020-020-0288-z.
2. Khashayar A, Bahari Z, Elliyeh M, et al. Therapeutic effects of berberine in metabolic diseases and diabetes mellitus. Rev Bras Farmacogn. 2021;31:272–281. doi:10.1007/s43450-021-00159-0.
3. Jin Y, Liu S, Ma Q, et al. Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes. Eur J Pharmacol. 2017;794:106–114. doi:10.1016/j.ejphar.2016.11.037.
4. Utami AR, Maksum IP, Deawati Y. Berberine and its study as an antidiabetic compound. Biology. 2023;12(7):973. doi:10.3390/biology12070973.
5. Ionescu OM, Frincu F, Mehedintu A, et al. Berberine: A promising therapeutic approach to polycystic ovary syndrome in infertile/pregnant women. Life (Basel). 2023;13(1):125. doi:10.3390/life13010125.
6. An N, Zhang G, Li Y, et al. Promising antioxidative effect of berberine in cardiovascular diseases. Front Pharmacol. 2022;13:837391. doi:10.3389/fphar.2022.837391.
7. Ilyas Z, Perna S, Al-thawadi S, et al. The effect of berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother. 2020;127:110137. doi:10.1016/j.biopha.2020.110137.
8. Jin Y, Khadka DB, Cho WJ. Pharmacological effects of berberine and its derivatives: A patent update. Expert Opin Ther Pat. 2016;26(2):229–243. doi:10.1517/13543776.2016.1118060.
9. Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020;14(5):564–582. doi:10.1007/s11684-019-0724-6.
10. Lau CW, Yao XQ, Chen ZY, et al. Cardiovascular actions of berberine. Cardiovasc Drug Rev. 2001;19(3):234–244. doi:10.1111/j.1527-3466.2001.tb00068.x.
11. Bagade A, Tumbigeremutt V, Pallavi G. Cardiovascular effects of berberine: A review of the literature. J Restor Med. 2017;6:100. doi:10.14200/jrm.2017.6.0100.
12. Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® berberine on glycemic control in patients with prediabetes: Double-blind, placebo-controlled, and randomized pilot trial. BMC Endocr Disord. 2023;23(1):190. doi:10.1186/s12902-023-01442-y.
13. Chang X, Wang Z, Zhang J, et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med. 2016;14(1):266. doi:10.1186/s12967-016-0982-x.
14. Laein GD, Boumeri E, Ghanbari S, et al. Neuroprotective effects of berberine in preclinical models of ischemic stroke: A systematic review. BMC Pharmacol Toxicol. 2025;26:40. doi:10.1186/s40360-025-00843-0.
15. Moon JM, Ratliff KM, Hagele AM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: A randomized, controlled, crossover pilot trial. Nutrients. 2022;14(1):124. doi:10.3390/nu14010124.
16. Blais JE, Huang X, Zhao JV. Overall and sex-specific effect of berberine for the treatment of dyslipidemia in adults: A systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2023;83:403–427. doi:10.1007/s40265-023-01841-4.
17. Mazurek A, Pawlicki M, Stachyrak K, et al. Berberine in the treatment of type 2 diabetes: Literature review. J Educ Health Sport. 2024;67:49000. doi:10.12775/JEHS.2024.67.49000.
18. Ochyra Ł, Łopuszyńska A, Pawlicki M, et al. Berberine in the treatment of polycystic ovary syndrome. J Educ Health Sport. 2022;12(4):309–314. doi:10.12775/JEHS.2022.12.04.024.
19. Rozwadowska P, Bator P, Razik M, et al. Anticancer properties of berberine: Analysis of the latest reports. J Educ Health Sport. 2024;61:73–86. doi:10.12775/JEHS.2024.61.005.
20. Xiong RG, Huang SY, Wu SX, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: An updated review. Molecules. 2022;27(14):4523. doi:10.3390/molecules27144523.
21. Kou Y, Tong B, Wu W, et al. Berberine improves chemo-sensitivity to cisplatin by enhancing cell apoptosis and repressing PI3K/AKT/mTOR signaling pathway in gastric cancer. Front Pharmacol. 2020;11:616251. doi:10.3389/fphar.2020.616251.
22. Wang J, Yang S, Cai X, et al. Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer. Oncotarget. 2016;7(46):76076–76086. doi:10.18632/oncotarget.12589.
23. Ye Y, Liu X, Wu N, et al. Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials. Front Pharmacol. 2021;12:653887. doi:10.3389/fphar.2021.653887.
24. Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045. doi:10.3389/fphar.2022.1015045.
25. Och A, Och M, Nowak R, et al. Berberine, a herbal metabolite in the metabolic syndrome: The risk factors, course, and consequences of the disease. Molecules. 2022;27(4):1351. doi:10.3390/molecules27041351.
26. Li Z, Wang Y, Xu Q, et al. Berberine and health outcomes: An umbrella review. Phytother Res. 2023;37(5):2051–2066. doi:10.1002/ptr.7806.
27. Guo HH, Shen HR, Wang LL, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother. 2023;163:114754. doi:10.1016/j.biopha.2023.114754.
28. Jurgiel J, Graniak A, Opyd P, et al. The role of berberine in polycystic ovary syndrome: A summary of knowledge. Ginekol Pol. 2024;95(4):276–284. doi:10.5603/gpl.95138.
29. Xia Y, Leung K, Zhao JV. Cost-effectiveness analysis of statins, berberine, and their combined use for primary prevention of cardiovascular disease. medRxiv. 2025; doi:10.1101/2025.02.20.25322455.
30. McCubrey JA, Lertpiriyapong K, Steelman LS, et al. Effects of resveratrol, curcumin, berberine, and other nutraceuticals on aging, cancer development, cancer stem cells, and microRNAs. Aging (Albany NY). 2017;9(6):1477–1536. doi:10.18632/aging.101250.
31. Guo HH, Shen HR, Wang LL, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother. 2023;163:114754. doi:10.1016/j.biopha.2023.114754.
32. McCubrey JA, Lertpiriyapong K, Steelman LS, et al. Effects of resveratrol, curcumin, berberine, and other nutraceuticals on aging, cancer development, cancer stem cells, and microRNAs. Aging (Albany NY). 2017;9(6):1477–1536. doi:10.18632/aging.101250.
33. Zamani M, Zarei M, Nikbaf-Shandiz M. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Front Nutr. 2022;9:1013055. doi:10.3389/fnut.2022.1013055.
34. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia, and hypertension. J Ethnopharmacol. 2015;161:69–81. doi:10.1016/j.jep.2014.09.049.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julia Piotrowska, Antonina Teresa Witkowska, Adrianna Domańska, Aleksandra Łubińska-Kowalska, Agata Żak-Gontarz, Aleksandra Minda, Adrianna Witkowska, Barbara Anna Zapalska, Justyna Janikowska, Krzysztof Julian Długosz, Monika Wendland

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 318
Number of citations: 0